Potential predictive value of plasma heat shock protein 90α in lung cancer

Ablation of elongation factor 2 kinase enhances heat-shock protein 90 chaperone expression and protects cells under proteotoxic stress

(2019) Jianling Xie et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

MicroRNA-27a downregulates the expression of Hsp90 and enhances the radiosensitivity in esophageal squamous cell carcinoma

(2019) Xintong Wang et al.   OncoTargets and Therapy

Identification of risk loci and a polygenic risk score for lung cancer: a large-scale prospective cohort study in Chinese populations

(2019) Juncheng Dai et al.   Lancet Respiratory Medicine

Systemic Therapy for Locally Advanced and Metastatic Non–Small Cell Lung Cancer

(2019) Kathryn C. Arbour et al.   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

Activity of HSP90 Inhibiton in a Metastatic Lung Cancer Patient With a Germline BRCA1 Mutation

(2018) Susana Cedrés et al.   JNCI-Journal of the National Cancer Institute

Activity of HSP90 Inhibiton in a Metastatic Lung Cancer Patient With a Germline BRCA1 Mutation

(2018) Susana Cedrés et al.   JNCI-Journal of the National Cancer Institute

Biomarkers in Lung Cancer Screening: Achievements, Promises, and Challenges

(2018) Luis M. Seijo et al.   Journal of Thoracic Oncology

Targeting HSP90-HDAC6 Regulating Network Implicates Precision Treatment of Breast Cancer

(2017) Shiyi Yu et al.   International Journal of Biological Sciences

Acquired Resistance to the Hsp90 Inhibitor, Ganetespib, in KRAS- Mutant NSCLC Is Mediated via Reactivation of the ERK–p90RSK–mTOR Signaling Network

(2017) Suman Chatterjee et al.   MOLECULAR CANCER THERAPEUTICS

Heat Shock Proteins and Cancer

(2017) Jianming Wu et al.   TRENDS IN PHARMACOLOGICAL SCIENCES

Cancer statistics in China, 2015

(2016) Wanqing Chen et al.   CA-A CANCER JOURNAL FOR CLINICIANS

The HSP90 inhibitor, NVP-AUY922, sensitizes KRAS-mutant non-small cell lung cancer with intrinsic resistance to MEK inhibitor, trametinib

(2016) Kang-Seo Park et al.   CANCER LETTERS

Plasma Levels of Heat Shock Protein 90 Alpha Associated with Lung Cancer Development and Treatment Responses

(2014) Y. Shi et al.   CLINICAL CANCER RESEARCH

Immunotherapy and lung cancer: current developments and novel targeted therapies

(2014) Duarte Domingues et al.   Immunotherapy

Secreted Heat Shock Protein 90α (HSP90α) Induces Nuclear Factor-κB-mediated TCF12 Protein Expression to Down-regulate E-cadherin and to Enhance Colorectal Cancer Cell Migration and Invasion

(2013) Wei-Shone Chen et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

Inhibition of HSP90 molecular chaperones: moving into the clinic

(2013) Rocio Garcia-Carbonero et al.   LANCET ONCOLOGY

Upregulation of Hsp90-beta and annexin A1 correlates with poor survival and lymphatic metastasis in lung cancer patients

(2012) Rong Biaoxue et al.   JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH

Heat shock proteins in oncology: Diagnostic biomarkers or therapeutic targets?

(2011) Ashraf A. Khalil et al.   BIOCHIMICA ET BIOPHYSICA ACTA-REVIEWS ON CANCER

The heat shock protein 90 inhibitor, AT13387, displays a long duration of action in vitro and in vivo in non-small cell lung cancer

(2011) Brent Graham et al.   CANCER SCIENCE

Sixty Years of CA: A Cancer Journal for Clinicians

(2010) T. Gansler et al.   CA-A CANCER JOURNAL FOR CLINICIANS

Targeting heat shock protein 90 with CUDC-305 overcomes erlotinib resistance in non-small cell lung cancer

(2009) R. Bao et al.   MOLECULAR CANCER THERAPEUTICS

The regulatory mechanism of Hsp90α secretion and its function in tumor malignancy

(2009) Xiaofeng Wang et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA